CTNNB1, catenin beta 1, 1499

N. diseases: 1368; N. variants: 68
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE Treatment with KU758 is associated with overall statistically significant upregulation of long noncoding RNA expression, including the tumor suppressor GAS5, which is implicated in the β-catenin and mammalian target of rapamycin pathways in adrenocortical carcinoma. 31561992 2020
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 GeneticVariation disease BEFREE Comprehensive analysis of CTNNB1 in adrenocortical carcinomas: Identification of novel mutations and correlation to survival. 29872083 2018
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE This study aimed to explore the effect of MED27 on the expression of epithelial-mesenchymal transition (EMT)-related proteins and β-catenin in adrenal cortical carcinoma (ACC). 29730647 2018
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 GeneticVariation disease BEFREE Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation. 29532999 2018
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 PosttranslationalModification disease BEFREE RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma. 28114280 2017
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 GeneticVariation disease CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011 2016
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 GeneticVariation disease BEFREE We sequenced PRKACA, GNAS and CTNNB1 genes in 108 patients, including 60 patients with CPAs (57 with unilateral and three with bilateral adenomas), 13 with nonfunctional adenomas, 12 with adrenocortical carcinomas (ACCs), 15 with primary bilateral macronodular hyperplasia (PBMAH) and eight with aldosterone and cortisol cosecreting adenomas. 27296931 2016
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE The pathogenesis of the adrenocortical cancer (ACC) involves integration of molecular signals and the interplay of different downstream pathways (i.e.IGFII/IGF1R, β-catenin, Wnt, ESR1). 26312764 2015
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition. 25823656 2015
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease CTD_human Integrated genomic characterization of adrenocortical carcinoma. 24747642 2014
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. 23409032 2013
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 AlteredExpression disease BEFREE Low SGK1 protein levels, but not nuclear β-catenin and phosphorylated AKT, were associated with poor overall survival in patients with adrenocortical carcinoma (P < 0.005; hazard ratio = 2.0; 95% confidence interval = 1.24-3.24), independent of tumor stage and GC secretion. 23055545 2012
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 AlteredExpression disease BEFREE Previous studies have identified overexpression of insulin-like growth factor 2 (IGF-2) and constitutive activation of β-catenin as key factors involved in the development of adrenocortical carcinoma. 21386792 2011
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE Additionally, the characterization of Wnt signaling through β-catenin in adrenal development, the demonstration of the involvement of BMP signaling in adrenocortical carcinoma growth regulation, and the discovery that ERCC1 expression levels can predict therapeutic response to platinum are just a few of the recent advances that promise to shed light on adrenocortical carcinoma biology. 21045685 2011
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 GeneticVariation disease BEFREE Mutations of β-catenin gene (CTNNB1) are frequent in adrenocortical adenomas (AA) and adrenocortical carcinomas (ACC). 21565795 2011
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. 21088256 2011
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE ACTs from patients with FAP and sporadic adrenocortical carcinomas (ACC) with abnormal β-catenin localization on immunohistochemistry but no somatic β-catenin mutations were studied. 20978149 2010
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE A role of beta-catenin (CTNNB1) in the molecular pathogenesis of adrenocortical carcinoma (ACC) has been suspected in adult ACC and pediatric pigmented nodular adrenocortical disease, but it has never been reported in pediatric ACC. 19863445 2010
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. 18544621 2008
CUI: C0206686
Disease: Adrenocortical carcinoma
Adrenocortical carcinoma
0.500 Biomarker disease BEFREE In adrenocortical adenomas, beta-catenin alterations are more frequent in nonfunctioning tumors, suggesting that beta-catenin pathway activation might be mostly involved in the development of nonsecreting adrenocortical adenomas and adrenocortical carcinomas. 16140927 2005